Special Issue Title:

Topic Collection "Current Novel Treatment of Patients with Ovarian Cancer"

Deadline for manuscript submissions: 31 December 2022

Print Special Issue Flyer (7)

Special Issue Editor

  • Guest Editor

    Samir A. Farghaly, MD, PhDE-MailWebsite

    The Weill Cornell University Medical College, New York, NY, USA

    Interests: Gynecological cancers minimally invasive surgery; Ovarian cancer targeted therapy; Ovarian cancer precision medicine; Immuno-oncology; Genomic profiling of ovarian cancer; Ovarian cancer biomarkers

  • Guest Editor

    Scott M. Eisenkop, MDE-MailWebsite

    Women's Cancer Center, Southern California, 4835 Van Nuys Blvd, Suite 208, Sherman Oaks, CA 91403, USA

    Interests: Hysterectomy; Lymph node dissection; Robot assisted surgery

Special Issue Information

Dear Colleagues,

Ovarian cancer is the seventh most common deathly cancer in women and accounted for almost 300,000 new cases, and almost 200,000 deaths annually worldwide in 2018.  In 2020, there will be approximately 21,750 new cases of ovarian cancer diagnosed and 13,940 ovarian cancer deaths in the USA. Primary debulking/cytoreductive surgery associated with a platinum/paclitaxel –based chemotherapy, is the standard care within treatment of advanced ovarian cancer (FIGO stage III and IV). The surgery could be achieved through open ultra-radical laparotomy surgery, laparoscopy, or robot-assisted laparoscopic surgery. Due to its late presentation, often stage III or IV, the prognosis is poor. Notwithstanding the good initial response to primary therapy, optimal debulking followed by the two-drug combination of carboplatin plus paclitaxel, responses are generally short-lived, and the clinical outcome is still unsatisfactory with median progression free survival rates from 16 to 21 months. Platinum resistant patients are often offered other chemotherapeutics, including doxorubicin, gemcitabine or topotecan monotherapy with PFS rates of 3-4 months. There is a pressing need to identify more efficient therapies. Anti-angiogenesis therapeutics, Bevacizumab cediranib, and trebananib offers relatively good results in both primary and recurrent ovarian cancer. Attempts to optimize chemotherapy have included weekly scheduling of paclitaxel and intraperitoneal chemotherapy. Trials using angiogenesis inhibition and poly-ADP ribose polymerase (PARP) inhibitors that have been FDA-approved for maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: olaparibrucaparib, and niraparib show an advantage in progression free survival. In addition, Trabectedin combined with liposomal doxorubicin play a role in patients with intermediate platinum sensitive disease. Hyper thermic intraperitoneal chemotherapy (HIPEC) and chemo-immunotherapy may become a promising therapy for the treatment of ovarian cancer. This publication is most timely, as our current knowledge and understanding of screening, the pathophysiology of ovarian cancer, molecular aspects of cancer progression and metastasis, and advances in minimally invasive surgery technology, has led to significant improvement of the relevant treatment modalities, including promising targeted and personalized therapy.

Prof. Dr. Samir A. Farghaly and Dr. Scott M. Eisenkop

Guest Editors

Keywords

Ovarian Cancer, Epithelial Ovarian Cancer, Optimal Debulking Surgery, Chemotherapy HIPEC, Platinum-resistant Ovarian Cancer, Anti-angiogenesis, PARP Inhibitors

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Published Papers (1 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences